Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 594-skin-ulcers-without-cc-mcc
    Ask Trek AI about this page

    Skin Ulcers without CC/MCC: Inpatient Reimbursement Overview

    DRG 594 encompasses inpatient stays for skin ulcers without Complication or Comorbidity or Major Complication or Comorbidity, focusing on wound management and related interventions. Accurate coding and documentation of ulcer etiology and the absence of Complication or Comorbidity or Major Complication or Comorbidity are important because they determine the Medicare payment and hospital case-mix classification.

    Customize your policy alerts

    Sign up for drg 594 policy alerts

    Get alerted when payer policies referencing 594 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 594 Overview

    DRG 594 covers inpatient admissions for patients treated primarily for skin ulcers when no Complication or Comorbidity or Major Complication or Comorbidity is present. It includes clinical management such as wound care, debridement, infection control, and evaluation for underlying causes like pressure, venous insufficiency, or arterial disease. This Diagnosis-Related Group matters because it groups expected resource use and establishes the Medicare payment for uncomplicated ulcer cases, affecting hospital reimbursement and case-mix reporting.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Studies of wound care interventions in hospitalized patients with stage III-IV pressure ulcers or chronic lower-extremity ulcers, comparing advanced dressings, biologic agents, or negative-pressure wound therapy versus standard moist wound care. These trials enroll inpatients who require debridement or intensive nursing care and measure time to wound closure, infection rates, need for surgical procedures, and resource utilization during the hospital stay. Results are highly relevant to providers for selecting effective acute wound management strategies and to payers for understanding inpatient length of stay, procedure use, and cost implications associated with different acute care pathways.
    • Comparative effectiveness trials assessing debridement techniques and perioperative infection prevention in patients with skin ulcers that are complicated by comorbidities such as diabetes or peripheral vascular disease. These studies focus on subgroups at higher risk for poor healing and examine outcomes like re-hospitalization, limb salvage, and short-term complication rates, often tracking care across the inpatient episode into the immediate post-discharge period. Findings inform clinical decision-making about which surgical or bedside debridement approaches and prophylactic care bundles reduce complications and downstream costs for medically complex patients within this DRG.
    • Post-discharge outcomes and care-coordination studies evaluating transitional care models, home health nursing intensity, and readmission reduction interventions for patients discharged after inpatient treatment of skin ulcers without major complications. These observational or pragmatic randomized studies follow patients through 30–90 days post-discharge to measure wound recurrence, emergency visits, readmissions, and outpatient resource use. For providers and payers, this research identifies which discharge planning and outpatient support strategies improve recovery, lower short-term readmission risk, and optimize total episode-of-care spending for this patient group.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.